AnGes,Inc.
| Market Cap | 22.0B |
| P/E Ratio | - |
| P/B Ratio | 7.21 |
| EPS | -119.53 |
| Dividend Yield | - |
| D/E Ratio | 1.16 |
| Current Ratio | 1.53 |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Currency | JPY |
Business Overview
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.
Key Financial Metrics
Profitability
Returns & Efficiency
Financial Health
| Industry | PHARMACEUTICAL |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Currency | JPY |
| Fiscal Year | 2024 |
Stock Chart
Full charting with technical indicators, candlestick, line charts, and more.
Company Profile
| Company Name | AnGes,Inc. |
| Ticker | 4563 |
| Exchange | TSE |
| Sector | Pharmaceutical |
| Industry | PHARMACEUTICAL |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Fiscal Year | 2024 |
| Currency | JPY |
| Market Cap | 22.0B |
| Revenue | - |
| Net Income | -28.1B |
| P/E Ratio | - |
| EPS | -119.53 |
| Net Margin | - |
| ROE | -13.0% |
| Dividend Yield | - |
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.